Lymphomatoid papulosis. A follow-up study of 30 patients.
Thirty patients, 13 female and 17 male, have been followed from 3 months to 22 years (mean, 81 months; median, 63 months) and special studies have been performed on a proportion of these in order to try to predict malignant evolution. Age at onset was from 20 to 70 years (mean, 43 years; median, 42 years). Duration of disease was from 1 to 30 years (mean, 119 months; median 161 months). Seven patients also had parapsoriasis en plaque or plaque-stage mycosis fungoides at the time of diagnosis and one patient had erythroderma. None of the 22 uncomplicated lymphomatoid papulosis patients developed malignant cutaneous lymphoma during the period of observation, while the remaining 8 patients who had concurrent parapsoriasis en plaque, mycosis fungoides, or erythroderma did not deteriorate further. Single-cell deoxyribonucleic acid (DNA) measurements on the dermal infiltrate were done in 13 patients and were abnormal in 7 patients. Two of these had greatly abnormal DNA histograms and at the same time an abnormal clinical presentation with multiple nodules and tumors. The remaining five patients had DNA histograms that indicated a potential for malignancy. Monoclonal antibody studies were performed on skin biopsy specimens of 10 patients. The dermal infiltrate was dominated by T-helper lymphocytes and some Hodgkin and Reed-Sternberg cells could be detected by the antibodies Ki-1, Ki-24, and Ki-27. Human T-lymphotropic virus type I (HTLV-I) antibodies were found in 3 of 18 patients examined. Treatment with psoralens plus ultraviolet A (PUVA) was effective (partial or complete remission) in six patients but they relapsed at cessation of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral / Q000032:analysis; D004247:DNA / Q000032:analysis; D017977:Deltaretrovirus / Q000276:immunology; D015480:Deltaretrovirus Antibodies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015474:Isotretinoin; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011701:PUVA Therapy; D011230:Precancerous Conditions / Q000473:pathology*; D012871:Skin Diseases / Q000188:drug therapy / Q000473:pathology*; D012878:Skin Neoplasms / Q000473:pathology*; D014212:Tretinoin / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D015480:Deltaretrovirus Antibodies; D014212:Tretinoin; D004247:DNA; D015474:Isotretinoin; D008727:Methotrexate